While innovative medicine supported Johnson & Johnson’s “in line” earnings for the third quarter of 2026, investors were disappointed to see older medicines carrying the bag.
J&J’s innovative medicines carried Q3 as medtech disappoints, but newer medicines absent Read More »
The takeover adds high-growth, high-margin products to Steris’ portfolio, analysts said.
Steris inks $2.1B Xodus buyout to expand consumables portfolio Read More »
Roche has gained access to a genetic obesity approach from China’s Rona Therapeutics for up to $100 million in upfront and near-term payments.
Roche expands obesity R&D footprint with Rona deal worth $1B+ Read More »
While BNT113 failed to improve progression-free survival in patients with a type of head and neck cancer during a Phase 3 trial, BioNTech is holding out hope for an overall survival win—but analysts say that outcome is now “less likely.”
The lawsuit isn’t a surprise, after Alignment told investors it would take all available actions to improve its quality scores.
Alignment sues CMS over 2027 Medicare Advantage star ratings crash Read More »
Syndax Pharmaceuticals will no longer test Niktimvo for idiopathic pulmonary fibrosis, but the company’s work to expand the drug’s label in chronic graft-versus-host disease, for which it was approved in 2024, will continue.
Syndax ends fibrosis program for Niktimvo after mid-stage disappointment Read More »
After Pfizer’s venture arm co-led Enodia Therapeutics’ $25 million seed round in January, the pharma has signed up to collaborate with the biotech on small-molecule drugs to eliminate pathogenic proteins where they’re being made.
Pfizer pens $500M+ deal with Enodia to destroy disease-causing proteins Read More »
Bellwether Johnson & Johnson will kick off the third quarter earnings reporting period on Tuesday, with analysts searching for news on business development, launch execution and more.
Analysts eye RevMed’s pancreatic cancer launch, Merck’s data blitz for Q3 earnings Read More »
Pocos nombres han moldeado el mundo moderno con la intensidad de Robert Noyce. Si hoy lees estas líneas desde una pantalla de ordenador, un smartphone o una tablet, se lo debes en gran medida a la visión y al ingenio de este físico e inventor estadounidense. Conocido cariñ …
Robert Noyce: El inventor del microchip y creador de Silicon Valley Read More »
El cerebro humano es una de las estructuras más complejas del universo conocido, pero opera con un principio de eficiencia energética implacable: prefiere la comodidad de tener razón al esfuerzo intelectual de buscar la verdad. En el corazón de esta dinámica cognit …
Por qué ignoramos las pruebas que contradicen lo que pensamos Read More »
